SCHEMBL6860195

SCHEMBL6860195

CCCCCC(=O)NS(=O)(=O)c1ccccc1NC(=O)c1ccccc1C#Cc1ccc(F)cc1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.38
GAA P10253 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
TBXA2R P21731 2/20 0.37
CA12 O43570 2/20 0.37
CA9 Q16790 2/20 0.37
PTPN1 P18031 1/20 0.36
FFAR1 O14842 1/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 1/20 0.36
ALOX12 P18054 1/20 0.36
KMT2A Q03164 1/20 0.36
CETP P11597 1/20 0.35
LMNA P02545 1/20 0.35
EPHX2 P34913 1/20 0.35
MRGPRX1 Q96LB2 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6866204 0.91 FFAR1 (0.38) TSHRHDAC3HDAC1FFAR1KDM4E
SCHEMBL6866219 0.90 RXFP1 (0.43) TSHRHDAC3HDAC1CA12CA9
SCHEMBL6864851 0.88 HDAC3 (0.38) TSHRHDAC3HDAC1CA12CA9
SCHEMBL7048492 0.82 PTGES (0.50) EPHX2
SCHEMBL6864874 0.81 RXFP1 (0.37) HDAC3HDAC1FFAR1ALDH1A1KMT2A
SCHEMBL7051034 0.81 PTGES (0.49) CETPEPHX2
SCHEMBL6860325 0.80 SLC16A3 (0.42) HDAC3HDAC1FFAR1KDM4ELMNA
SCHEMBL6864455 0.79 ACACB (0.38) GAAHDAC3HDAC1FFAR1KDM4E
SCHEMBL6860157 0.78 CA2 (0.53) CA12CA9KMT2A
SCHEMBL7080234 0.77 MMP2 (0.43) TSHRHDAC3HDAC1FFAR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812252-B2 ACYLSULFONAMIDE DERIVATIVES CONTAINING FLUOROSUBSTITUTEDPHENYLETHYNYL GROUP HAVING A HYPOGLYCEMIC EFFECT AND FREE OF THE SIDE EFFECT AJINOMOTO CO., INC. (JP) 2004-11-02 US disclosed
US-20030191323-A1 Hypoglycemic agent AJINOMOTO CO., INC. (JP) 2003-10-09 US disclosed
US-20030181764-A1 Acylsulfonamide derivatives AJINOMOTO CO. INC (JP) 2003-09-25 US disclosed
EP-1316548-A1 ACYLSULFONAMIDE DERIVATIVES Ajinomoto Co., Inc. (JP) 2003-06-04 EP disclosed
EP-1300142-A1 HYPOGLYCEMICS Ajinomoto Co., Inc. (JP) 2003-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181764-A1 Acylsulfonamide derivatives DPP4, SLC5A2, GLP1R TSHR 1566/4885GAA 130/4885HDAC3 33/4885
US-20030191323-A1 Hypoglycemic agent GPR119, IAPP, SLC5A2 TSHR 3150/4885GAA 40/4885HDAC3 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.